BioMarin Prices $850M Senior Notes and Completes Syndication for $2B Term Loan B to Fund Amicus Acquisition

summarizeSummary

BioMarin Pharmaceutical Inc. announced the pricing of $850 million in senior unsecured notes and the completion of syndication for a $2 billion senior secured term loan B facility, both intended to fund the pending acquisition of Amicus Therapeutics, Inc.

check_boxKey Events

• Senior Notes Priced

  BioMarin priced $850 million of 5.500% senior unsecured notes due 2034 in a private placement, with the offering expected to close on February 12, 2026. This finalizes terms for a portion of the debt financing package initiated on January 26, 2026.

• Term Loan B Syndication Completed

  The company completed the syndication of a new $2 billion senior secured term loan "B" facility, which is part of a larger senior secured credit facility package.

• Acquisition Funding Secured

  Proceeds from the notes and term facilities, along with cash on hand, will fund the pending acquisition of Amicus Therapeutics, Inc. and related fees and expenses.

auto_awesomeAnalysis

This 8-K provides critical updates on BioMarin's substantial debt financing package, which was previously announced on January 26, 2026. It finalizes the terms and pricing of $850 million in senior unsecured notes at 5.500% and confirms the completion of syndication for the $2 billion Term Loan B facility. These are significant steps in securing the necessary capital for the Amicus Therapeutics acquisition. While increasing the company's debt load, the successful execution of this financing demonstrates market confidence and ensures funding for a key strategic growth initiative. Investors should monitor the closing of the acquisition and the integration of Amicus.